Literature DB >> 33181351

The NLRP3 inflammasome triggers sterile neuroinflammation and Alzheimer's disease.

Mark T Milner1, Madhavi Maddugoda1, Jürgen Götz2, Sabrina S Burgener3, Kate Schroder4.   

Abstract

To maintain homeostasis, an organism must detect and resolve sterile tissue damage. The NLRP3 inflammasome coordinates such processes to clear tissue damage and induce repair. Dysregulated NLRP3 inflammasome activity, however, drives many conditions including Alzheimer's disease (AD). Recent reports posit that β-amyloid and tau aggregates trigger destructive NLRP3 inflammasome signalling in the brain, leading to AD pathophysiology and cognitive decline. Other endogenous molecules (e.g. TNF, ATP, serum amyloid A), as well as dysbiosis, can induce peripheral or central inflammation and thereby promote microglial NLRP3 inflammasome signalling and resultant AD. The NLRP3 inflammasome is thus emerging as a critical driver of sterile neuroinflammation and the resultant pathogenesis and progression of AD.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33181351     DOI: 10.1016/j.coi.2020.10.011

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  13 in total

1.  Contribution of the innate and adaptive immune systems to aortic dilation in murine mucopolysaccharidosis type I.

Authors:  Elizabeth Braunlin; Juan E Abrahante; Ron McElmurry; Michael Evans; Miles Smith; Davis Seelig; M Gerard O'Sullivan; Jakub Tolar; Chester B Whitley; R Scott McIvor
Journal:  Mol Genet Metab       Date:  2022-02-03       Impact factor: 4.204

2.  Dapsone is an anticatalysis for Alzheimer's disease exacerbation.

Authors:  Jong Hoon Lee; Badar Kanwar; Chul Joong Lee; Consolato Sergi; Michael D Coleman
Journal:  iScience       Date:  2022-04-20

Review 3.  Phagocytic clearance of apoptotic, necrotic, necroptotic and pyroptotic cells.

Authors:  Georgia K Atkin-Smith
Journal:  Biochem Soc Trans       Date:  2021-04-30       Impact factor: 5.407

Review 4.  Molecular Hydrogen as a Novel Protective Agent against Pre-Symptomatic Diseases.

Authors:  Haru Yamamoto; Yusuke Ichikawa; Shin-Ichi Hirano; Bunpei Sato; Yoshiyasu Takefuji; Fumitake Satoh
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

5.  NLRP3 Inflammasome Blocking as a Potential Treatment of Central Insulin Resistance in Early-Stage Alzheimer's Disease.

Authors:  Yulia K Komleva; Ilia V Potapenko; Olga L Lopatina; Yana V Gorina; Anatoly Chernykh; Elena D Khilazheva; Alla B Salmina; Anton N Shuvaev
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

6.  Electroacupuncture Inhibits NLRP3 Activation by Regulating CMPK2 After Spinal Cord Injury.

Authors:  Yi Chen; Lei Wu; Mengting Shi; Danyi Zeng; Rong Hu; Xingying Wu; Shijun Han; Kelin He; Haipeng Xu; XiaoMei Shao; Ruijie Ma
Journal:  Front Immunol       Date:  2022-03-24       Impact factor: 7.561

Review 7.  Gut Microbiota Interact With the Brain Through Systemic Chronic Inflammation: Implications on Neuroinflammation, Neurodegeneration, and Aging.

Authors:  Yi Mou; Yu Du; Lixing Zhou; Jirong Yue; Xianliang Hu; Yixin Liu; Sao Chen; Xiufang Lin; Gongchang Zhang; Hengyi Xiao; Birong Dong
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

Review 8.  Targeting NLRP3-Mediated Neuroinflammation in Alzheimer's Disease Treatment.

Authors:  Julia Barczuk; Natalia Siwecka; Weronika Lusa; Wioletta Rozpędek-Kamińska; Ewa Kucharska; Ireneusz Majsterek
Journal:  Int J Mol Sci       Date:  2022-08-11       Impact factor: 6.208

9.  Milrinone Ameliorates the Neuroinflammation and Memory Function of Alzheimer's Disease in an APP/PS1 Mouse Model.

Authors:  Qingyou Chen; Yue Yin; Li Li; Yanjiao Zhang; Wei He; Yan Shi
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-30       Impact factor: 2.570

10.  Enduring glucocorticoid-evoked exacerbation of synaptic plasticity disruption in male rats modelling early Alzheimer's disease amyloidosis.

Authors:  Yingjie Qi; Igor Klyubin; Tomas Ondrejcak; Neng-Wei Hu; Michael J Rowan
Journal:  Neuropsychopharmacology       Date:  2021-06-29       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.